These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30404763)

  • 1. The key role of T cells in Parkinson's disease pathogenesis and therapy.
    Baird JK; Bourdette D; Meshul CK; Quinn JF
    Parkinsonism Relat Disord; 2019 Mar; 60():25-31. PubMed ID: 30404763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of T cells in the pathogenesis of Parkinson's disease.
    Chen Z; Chen S; Liu J
    Prog Neurobiol; 2018 Oct; 169():1-23. PubMed ID: 30114440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 cells: a promising therapeutic target for Parkinson's disease?
    Prots I; Winner B
    Expert Opin Ther Targets; 2019 Apr; 23(4):309-314. PubMed ID: 30871383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein network exploration prioritizes targets for modulating neuroinflammation in Parkinson's disease.
    Bonte MA; El Idrissi F; Gressier B; Devos D; Belarbi K
    Int Immunopharmacol; 2021 Jun; 95():107526. PubMed ID: 33756233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments.
    von Euler Chelpin M; Vorup-Jensen T
    Scand J Immunol; 2017 May; 85(5):321-330. PubMed ID: 28231624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
    Olson KE; Gendelman HE
    Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Hirsch EC; Hunot S
    Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention.
    Lee Y; Lee S; Chang SC; Lee J
    Arch Pharm Res; 2019 May; 42(5):416-425. PubMed ID: 30830660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Dopaminergic System in Autoimmunity.
    Vidal PM; Pacheco R
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):57-73. PubMed ID: 30661214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies.
    Rocha NP; de Miranda AS; Teixeira AL
    Biomed Res Int; 2015; 2015():628192. PubMed ID: 26295044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases.
    Boyko AA; Troyanova NI; Kovalenko EI; Sapozhnikov AM
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models.
    Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS
    Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Lymphocytes in Parkinson's Disease.
    Contaldi E; Magistrelli L; Comi C
    J Parkinsons Dis; 2022; 12(s1):S65-S74. PubMed ID: 35253782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into Immune-Mediated Mechanisms in Parkinson's Disease.
    Tan JSY; Chao YX; Rötzschke O; Tan EK
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic targets for Parkinson's disease.
    Stoessl J
    Expert Opin Ther Targets; 2008 Apr; 12(4):425-36. PubMed ID: 18348679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease.
    Caronti B; Antonini G; Calderaro C; Ruggieri S; Palladini G; Pontieri FE; Colosimo C
    J Neural Transm (Vienna); 2001; 108(7):803-7. PubMed ID: 11515746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for trials of neuroprotection in Parkinson's disease.
    Agarwal PA; Stoessl AJ
    Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.